Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Launched by IMPERIAL COLLEGE LONDON · Sep 29, 2005
Trial Information
Current as of July 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called Hereditary Haemorrhagic Telangiectasia (HHT), which can cause abnormal blood vessel growth and bleeding. The study is being conducted at Hammersmith Hospital in London and aims to gather information about patients who have this condition, particularly those with pulmonary arteriovenous malformations (which are abnormal connections between arteries and veins in the lungs). This research will help doctors understand more about HHT and improve care for patients.
Anyone who is a patient at Hammersmith Hospital with this condition may be eligible to participate in the study, as there are no specific exclusions. If you choose to join, you will be part of a review process where your medical history and treatment will be looked at to help gather important information. Participating in this study could contribute to better understanding and treatment options for future patients with HHT.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients attending Hammersmith Hospital
- Exclusion Criteria:
- • None
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Claire L Shovlin
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials